Compound 200 Mg Sulfate De Fer + 0.25mg Folic Acid (GMP medicine manufacture)

For pregnant women to prevent maternal anaemia, puerperal sepsis, low birth weight, and preterm birth in pregnant women and adolescent girls.
To treat severe anaemia in non-pregnant adolescents.
For the prevention of neural tube defects and other congenital malformations in the foetus
 

The present report demonstrates that ferrous bisglycinate plus folinic acid (24 mg elemental iron) supplementation can improve hematological and iron status in pregnant women with iron deficiency, with fewer side effects than a ferrous fumarate (66 mg elemental iron) preparation. Therefore, the commercial product may be considered feasible for clinical and nutritional strategies to manage iron deficiency during pregnancy, reaffirming the need for more efficient iron delivery and consideration of physiological aspects of iron homeostasis rather than simply titrating levels or frequencies.

Folic acid, as it is biochemically inactive, is converted to tetrahydrofolic acid and methyltetrahydrofolate by dihydrofolate reductase (DHFR). These folic acid congeners are transported across cells by receptor-mediated endocytosis where they are needed to maintain normal erythropoiesis, synthesize purine and thymidylate nucleic acids, interconvert amino acids, methylate tRNA, and generate and use formate. Using vitamin B12 as a cofactor, folic acid can normalize high homocysteine levels by remethylation of homocysteine to methionine via methionine synthetase.